Blueprint Medicines Corporation

Lexicon Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Actinium Pharmaceuticals, Limited

Yulian Zhang

Joseph L Kim

Brian Lewis Hodous

Douglas Wilson

Andreas Peter Termin

Dean Wilson

Yingzhi Bi

Michael Alan Green

Kevin J Wilson

Esther Martinborough

Kenneth Gordon Carson

Timothy Donald Neubert

Jesus E Gonzalez, Iii

Lucian V DiPietro

Giovanni Cianchetta

Roger D Tung

Lev T D Fanning

Chandrasekhar V Miduturu

Steven Mark Wenglowsky

Godwin Kwame Kumi

Benjamin John Petzoldt

John E Macor

Joanne J Bronson

Paul E Fleming

Carolyn Diane Dzierba

Nicole Zimmerman

Alan Main

David Kimball

Soojin Kwon

Greg Zipp

Godwin Kumi

Peter D J Grootenhuis

Jesus Arturo Gonzalez

Nicole Hilgraf

Cynthia Anne Fink

Michael Voronkov

David Brent Rawlins

Nicole Zimmermann

Lev Tyler Dewey Fanning

Natasja Brooijmans

Gregory Glenn Zipp

Glenn Gregory Zipp

Jian Jim Wang

Timothy J Guzi

Jason D Brubaker

Peter Diederik Jan Grootenhuis

Peter Grootenhuis

Pramod Virupax Joshi

Spencer David Kimball

Paul Krenitsky

Richard A Hartz

Ross Mabon

Bryce Alden Harrison

Kaushik J Dave

Vijay T Ahuja

Li Dong

Jiancheng Wang

Lev Fanning

S Roy Kimura

Ying Jade Liu

Dennis Stewart Rice

Jian Wang

Michael Walter Gardyan

Zhi Liang

Michael Green

Michael Victor Voronkov

Dennis S Rice

Dean M Wilson

Jesus E Gonzalez Iii Iii

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Compositions useful for treating disorders related to KIT

Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity 

2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

A patient specific therapeutic composition provided in a single dose container, the total volume of which may be administered to a patient in a single treatment session. The composition includes a monoclonal antibody having a labeled fraction and an unlabeled fraction, and a pharmaceutically acceptable carrier. The label may be any of a radioisotope or a drug such as a chemotherapeutic or cytotoxic agent. The amount of the monoclonal antibody and any conjugated label molecule may depend on at least one patient specific parameter selected from a patient weight, a patient age, a patient height, a patient gender, a patient medical condition, and a patient medical history. Methods of administration, production, and articles of manufacture comprising the patient specific therapeutic composition are also disclosed.

Infusion administration of conjugated monoclonal antibodies

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Compounds useful for treating disorders related to RET

Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.

Compositions useful for treating disorders related to kit and PDGFR

Compositions useful for treating disorders related to kit

Compounds and compositions useful for treating disorders related to Kit are described herein.

Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein.

Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R, Rand Rare defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R, Rand Rare defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by adaptor associated kinase 1 activity are also disclosed.

Growing community of inventors

Acton, MA, United States of America

Yulian Zhang